Vaughn Eyvazian, MD
Cardiovascular Disease · Los Angeles, CANPI 1295129492
Payments from drug & device makers
Across 406 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$3K
- Boston Scientific$2K
- Abbott$1K
- Philips North America LLC$1K
- Medtronic$991
- Shockwave Medical, Inc$690
- plus $4K from 32 others
What the payments were for
- Travel & lodging$2,08116%
- Food & beverage$10,87483%
- Education$1441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 84 | $2,774 |
| Boston Scientific | 31 | $2,348 |
| Abbott | 35 | $1,122 |
| Philips North America LLC | 9 | $1,050 |
| Medtronic | 28 | $991 |
| Shockwave Medical, Inc | 17 | $690 |
| Amgen | 32 | $478 |
| AstraZeneca | 12 | $402 |
| Pfizer | 32 | $391 |
| Merck | 13 | $307 |
| Novartis | 16 | $277 |
| E.r. Squibb & Sons, L.L.C. | 15 | $274 |
| Alnylam Pharmaceuticals Inc. | 10 | $218 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $213 |
| Cardiva Medical, Inc. | 1 | $200 |
| Kiniksa Pharmaceuticals International, PLC | 8 | $183 |
| Heartflow, Inc. | 2 | $158 |
| Novo Nordisk | 6 | $150 |
| Lexicon Pharmaceuticals, Inc. | 5 | $147 |
| Johnson & Johnson | 5 | $99 |
| Baxter Healthcare | 4 | $77 |
| Bayer | 3 | $70 |
| Amarin Pharma, Inc. | 3 | $63 |
| Edwards Lifesciences | 3 | $58 |
| Bridgebio Pharma, Inc. | 2 | $56 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $44 |
| Cleerly, Inc. | 1 | $30 |
| United Therapeutics Corporation | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Altathera Pharmaceuticals LLC | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| Cordis US CORP. | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JETSTREAM SC$654
- ELUVIA$638
- (9520) IGT Devices Undivided$636
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$523
- COREVALVE EVOLUT R$429
- Impella$411
- Cardiva VASCADE MVP VVCS 6-12F$200
- OPTIS$178
- DRAGONFLY OPSTAR$149
- Resolute$144
- FFRct$143
- GENERAL - THERAPIES$140
- ROTAPRO$131
- FARXIGA$121
- (6571) Eagle Eye$117
- AVVIGO Guidance System$112
- COROFLOW$108
How this compares
$13,100 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $107,905 |
| FarxigaDapagliflozin Propanediol | 61 | $79,490 |
| BrilintaTicagrelor | 76 | $54,320 |
| EntrestoSacubitril/Valsartan | 38 | $53,387 |
| Repatha SureclickEvolocumab | 44 | $45,380 |
| JardianceEmpagliflozin | 18 | $18,613 |
| Rosuvastatin Calcium | 88 | $1,904 |
| Metoprolol Succinate | 135 | $1,846 |
| Atorvastatin Calcium | 146 | $1,311 |
| Amlodipine Besylate | 116 | $910 |
| Carvedilol | 63 | $668 |
| Lisinopril | 74 | $635 |
| ClopidogrelClopidogrel Bisulfate | 65 | $605 |
| Spironolactone | 42 | $575 |
| Furosemide | 80 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $402 | $133,810137 claims |
| PfizerEliquis | $391 | $107,90576 claims |
| NovartisEntresto | $277 | $53,38738 claims |
| Boehringer IngelheimJardiance | $18 | $18,61318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Kalyanam ShivkumarLos Angeles$2.9M
- Priscilla HsueLos Angeles$2.3M
- Cathleen Bairey-MerzLos Angeles$1.4M
- Somjot BrarLos Angeles$1.2M
- Freny ModyLos Angeles$960K
- Jamil AboulhosnLos Angeles$683K
- Parveen GargLos Angeles$653K
- Karol WatsonLos Angeles$553K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.